Clinical trial · no report yet · Phase 3
DASL-HiCaP
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
- NCT04136353 ↗
- Active not recruiting
- University of Sydney
- 47 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 23 | |
| Podcasts | 12 | |
| X threads | 12 |
The trial
ClinicalTrials.gov- Official title
- DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Darolutamide; Placebo oral tablet; Luteinizing Hormone-Releasing Hormone Analog; External Beam Radiotherapy
- Arms
- Darolutamide · Experimental
- Placebo · Placebo comparator
- Enrollment
- 1,100
- Primary outcomes
- Metastasis-free survival
- Sponsor
- University of Sydney with Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Bayer, Cancer Trials Ireland, Canadian Cancer Trials Group, Memorial Sloan Kettering Cancer Center, Prostate Cancer Clinical Trials Consortium
- Start
- Mar 31, 2020
- Primary completion
- Jan 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04136353 · updated May 6, 2026